MedPage Today—August 18, 2015
MedPage Today takes a look at a recent phase II study on the safety and efficacy of edratide in patients with active systemic lupus erythematosus (SLE). While the trial’s primary endpoints were not met, edratide showed promising clinical benefits among patients with SLE.
Michael D. Lockshin, MD, rheumatologist at Hospital for Special Surgery who is not involved in the study, says, "It's a really interesting concept, completely different than anything we've done, but this is a good news, bad news story. The good news is that it's a pretty interesting mechanism and the data that are shown do show an effect. It's a different way of treating patients – an imaginative way."
To read the full story, please visit MedPageToday.com.